Pathophysiology of Osteonecrosis of the Jaw in Patients Treated with Bisphosphonate by Tomislav Badel et al.
Coll. Antropol. 37 (2013) 2: 645–651
Review
Pathophysiology of Osteonecrosis of the Jaw in
Patients Treated with Bisphosphonate
Tomislav Badel1, Ivana Savi} Pavi~in2, Andreja Jelini} Carek3, Kata Ro{in-Grget4
and \ur|ica Grbe{a5
1 University of Zagreb, School of Dental Medicine, Department of Removable Prosthodontics, Zagreb, Croatia
2 University of Zagreb, School of Dental Medicine, Department of Dental Anthropology, School of Dental Medicine, Zagreb, Croatia
3 University of Zagreb, School of Dental Medicine, Department of Fixed Prosthodontics, Zagreb, Croatia
4 University of Zagreb, School of Dental Medicine, Department of Pharmacology, School of Dental Medicine, Zagreb, Croatia
5 University of Zagreb, School of Medicine, Department of Histology and Embryology, Zagreb, Croatia
A B S T R A C T
Apart from the well-known mechanism of bisphosphonates’ cellular effect, embryonic development and the specific
features of alveolar bone homeostasis have been discussed. The unique ethiopathogenic mechanism which relates osteo-
necrosis of the jaw and bisphosphonates treatment has not been explained. The emphasis lies on the toxicological effects
of bisphosphonates on the physiology of the alveolar bone and on the lasting effect of tooth extraction followed by an infec-
tion of the extraction wound and consequent progression into deeper layers of osseous tissue. Epithelial infection in-
cludes microbiological findings of Actinomyces species. The risk is pronounced in oncological patients treated with bis-
phosphonates intravenously in relatively large doses and during a longer period of time, especially with highly potent
nitrogen-containing bisphosphonates pamidronate and zoledronate. This review of bisphosphonate-related osteonecrosis
of the jaw stresses the significance of some other risk factors (corticosteroids, chemotherapy, tumour tissue etc.) of necro-
sis development – more precisely of osteomyelitis of the jaw if the microbiological component of the diseases has been
taken into account, while the role of the bisphosphonates becomes minor. There is no gold standard for the treatment of
jaw osteonecrosis; rather, palliative and minimally invasive treatment is applied, without subsequent oral surgical inter-
ventions. Since there is a significant risk of jaw osteonecrosis in oncological patients, the level of oral health is an impor-
tant factor for the indication of intravenous bisphosphonates treatment.
Key word: bisphosphonates, osteonecrosis, jaw, pathophysiology, embryology
Introduction
Since 2003, when the special subtype of osteonecrosis,
which develops on jaw bones after use bisphosphonates
(BPs) and is therefore called BPs-related osteonecrosis of
the jaw (BRONJ), was first identified, it has become a
public health issue1. The aim of the paper is to review
current scientific facts which explain the causal relation-
ship between the onset of jaw osteonecrosis and the ef-
fects of BPs.
Bone Homeostasis
In the course of embryonic development, mineralisa-
tion of non-mineralised osseous tissue occurs via intra-
membranous and endochondral ossification. Intramem-
branous ossification is mineralisation of osteoids as
young non-mineralised bone originating from the primi-
tive connective tissue (mesenchyme) without the pres-
ence of cartilaginous tissue. Endochondral ossification is
the formation of the osteoid within a hyaline cartilage
model. It is typical for long bones and bone matrix re-
places the cartilage model. Primary centre of ossification
develops in the central part of the diaphysis and subse-
quently, the secondary centres of ossification develop in
epiphysis. Process of bone elongation occurs at ossifica-
tion centres’ junction via the still present cartilage which
is called epiphyseal growth plate and at the same time,
the whole skeleton develops2–4.
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Bone mineralisation of the mandible occurs via two
types of ossification of the base of one mesenchymal bone
originating from the neural crest cells. A major part of
the mandible, including the alveolar bone is ossified
intramembraneously and laterally from the first bran-
chial arch cartilage (Meckel’s cartilage). A carrot shaped
cartilaginous condyle wherein the endochondral type of
ossification occurs in a later phase is placed posteriorly.
The bones of the membranous viscerocranium including
the maxillary bone develop exclusively by intramem-
branous ossification from the maxillary process of the
first pharyngeal arch5,6.
Formation and resorption are two opposing processes
of continuous internal remodelling and renewal of the
bone tissue throughout adult life. Mineralised bone tis-
sue is continually remodelled by the action of the basic
multi-cellular unit2. Osteoblasts, cells responsible for the
formation of new bone together with osteoclasts, cells re-
sponsible for the resorption of the existing bone, oppos-
ing each other in their effects, but still within a complex
system of mutual signals (cross-talk), are directly impor-
tant for the understanding of BPs’ effects7,8.
In the physiological bone-renewal cycle, the osteoclast
begins the bone resorption process, in response to the
parthyroid hormone and occupies a shallow concavity
called Howship’s lacuna2,3. In the initial phase (called ac-
cording to Matsuo and Irie8, non-differentiated hemato-
poietic stem cells (monocytes/macrophages) are recruited
into osteoclast precursors. The presence of cell surface
receptors called receptor activator of nuclear factor
kappaB ligand (RANKL) and monocyte-colony stimulat-
ing factor (M-CSF) is necessary for the regulation of
osteoclastogenesis maturation as well as for osteoclasts’
function as giant multinucleated cells2,9,10.
RANKL is a cytokine (transmembrane glycoprotein)
and the essential osteoclastogenic ligand which belongs
to tumour necrosis factor ligand family. RANKL is pro-
duced by stromal cells, especially by bone lining cells.
RANKL attaches itself to RANK (receptor activator of
nuclear factor kappaB), a receptor on the cell surface of
osteoclasts and osteoclast precursors, in order to stimu-
late proliferation and differentiation of cells to form the
osteoclast phenotype and also to inhibit apoptosis. Bone
lining cells belong to the fully differentiated osteoblasts
which are situated on the bone surface. Unlike osteo-
blasts, which are cuboidal and produce M-CSF, the bone
lining cells are flat and are not bone-forming8–10.
Osteocytes are embedded in the bone matrix and be-
long to the osteoblast lineage. Osteocytes are considered
to be the mechanosensors of bone tissue. Bone lining
cells transmit the majority of mechanical signals to os-
teocytes. Bone remodelling takes place in response to
osteocyte apoptosis due to microcrack damage or lack of
mechanical loading. There is a correlation between os-
teoclastogenesis and both osteoblast lineage cells – os-
teocytes and osteoblasts: osteoclastogenesis is regulated
by RANKL-expressing osteoblasts and RANK-expressing
osteoclast precursors. The catabolic effects of RANKL
are prevented by osteoprotegerin (OPG), a key modulator
of activation of RANK by RANKL. OPG binds RANKL
and thereby prevents activation of RANK. The osteoclast
actively resorbs bone by developing a ruffed border on its
surface to the bone surface. The formation of this folded
membrane is caused by massive hydrochloric acid (to a
pH of 1) secretion in the area of Howship’s lacuna for de-
mineralisation of apatites. The organic matrix is de-
graded by specific enzymes (eg. proteases like cathepsin
K)2,8,11.
During the transition phase osteoclasts induce osteo-
blast differentiation by producing membrane-bound mol-
ecules, such as cytokine transforming growth factor. It is
believed that the released calcium binds to polyphos-
phates in the course of osteoclastic bone resorption since
it is a biologically available reservoir of high-concentra-
tion calcium and orthophosphates which are necessary
for the further process of bone remodelling. The phos-
phoanhydride bond (P-O-P) enables the hydrolytic poly-
phosphate degradation at neutral pH, the degradation of
which enables the precipitation of free calcium into the
newly-formed apatites. In the transition phase osteoclas-
tic bone resorption is stopped because osteoclasts un-
dergo apoptosis in Howship’s lacuna12.
While bone resorption lasts about 3 weeks, the termi-
nation phase develops slowly, about 3 months. The osteo-
clasts differentiation is suppressed in this phase, mostly
through OPG secreted by osteoblasts. After the forma-
tion of an osteid within the resorbed lacuna by osteo-
blasts, osteocytes are differentiated within the young
bone whereas osteoblasts transform into flattened bone
lining cells8,13.
BPs
BPs are analogues of pyrophosphates, wherein the
carbon atom (P-C-P) is the geminal atom of the molecule
in the phosphate-etheric chain, which makes them resis-
tant to hydrolysis and also to the effects of pyrophospha-
tase in a cellular medium (Table 1). Two additional sec-
ondary covalent chains (R1 and R2) which may contain
different atoms such as carbon, oxygen, chlorine, sulphur
and nitrogen12,13 are bound to the geminal carbon atom14,15.
R1 chain determines the first important property of
BP; they bind to bivalent metal ions, calcium being the
most important to bones, via lateral oxygen atoms. This
enables binding of BPs to the apatites of the skeletal sys-
tem, where they remain firmly bound to the structure of
bone tissue. The pronounced affinity towards calcium
ions is achieved by adding the hydroxyl group to R1 sec-
ondary molecular chain, which is the structure of most
bisphosphonates14,15.
R2 lateral chain structure also affects inhibition of
bone resorption. Since the efficacy of etidronates with
the methyl group (–CH3) and some others from the group
of non-nitrogen BPs (colodronate, tiludronate) is limited,
a new clinically relevant nitrogen-containing group of
BPs was created by inserting nitrogen into the molecular
structure. Alkyl-amino (pamidronate, alendronate, iban-
dronate) and the heterocyclic nitrogen group (risedro-










nate, zoledronate) at the end of the R2 chain increases
the affinity of BPs to bone tissue and its anti-resorption
activity15,16.
The cellular effect of BPs is twofold depending on
whether they have the nitrogen component. Non-nitro-
gen-containing BPs have less complex effects. They could
be metabolised in the osteoclast cytosol to nonhydro-
lyzable methylene-containing (AppCp-type) analogues of
adenosine triphosphate (ATP) that contain the P-C-P
group of the BP in place of P-O-P. The accumulation of
ATP analogues in osteoclasts has a cytotoxic effect, in-
hibiting numerous intracellular metabolic enzymes, and
inducing osteoclast apoptosis. Nitrogen-containing BPs
inhibit a key enzyme farnesyl diphosphate synthase
(FPP-synthase) in the mevalonate pathway. Apart from
the cholesterol synthesis, the function of this pathway is
prenylation, that is, a process of hydrophobe molecule
(isoprenoid lipids, the so-called GTPases, farnesyl and
more important geranylgeranyl) binding to the proteins
of the cell membrane. They anchor to the proteins in cell
membranes and are also required for protein to protein
interactions, and finally apoptosis. The molecular mech-
anism of nitrogenous BPs on osteoclasts may actually be
due to the accumulation of unprenylated small GTPases
in their active state rather than loss of the prenylated
proteins. This leads to osteoclasts’ apoptosis15–18.
BRONJ
The osteonecrosis of the jaw is not a new pathological
condition since the direct etiopathogenic relation to toxic
effects of yellow phosphorus on human body has been
known for a long time19, 20. The BRONJ diagnosis (Table
2) includes the following criteria: present or past bis-
phosphonate treatment and open necrotic wound lasting
more than 8 weeks with no history of radiotherapy to the
maxillofacial region. The three basic stages of BRONJ
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tiludronate (Skelid) Paget disease No







Oral 1600–3200 mg day–1
IV 60 mg
10 15 hrs
alendronate (Fosamax) Osteoporosis Yes
Oral 10 mg day–1
Oral 70 mg week–1
100–1000
10 yrs
risedronate (Actonel) Osteoporosis Yes
Oral 5 mg day–1









Oral 2.5 mg day–1
Oral 150 mg month–1













Yes IV 4 mg every 3 weeks >10000
Initial 0.24–1.87 hrs
Terminal 146 hrs
†Relative to etidronate; IV intravenous
TABLE 2
PRESENTING FEATURES OF BISPHOSPHONATES-RELATED OSTEONECROSIS OF THE JAW
Symptoms Signs
Bone pain Alveolar bone loss
Paraesthesia Resorption
Neuropathic pain Inferior alveolar canal narrowing
Loosening of teeth Dense woven alveolar bone
Odontalgia Thickening of the periodontal ligament









which also determine the extent of conservative surgical
procedures are the following: stage 1, symptomatic, ex-
posed and necrotic bone without infection; stage 2, pain-
ful exposed and necrotic bone with clinically evident in-
fection; and stage 3, complications which include exten-
ding, exposed and necrotic bone, pathological fractures,
fistulisation and osteolysis of inferior border of the man-
dible or sinus floor on the maxilla. Since the development
of asymptomatic BRONJ is possible, the 0 stage has been
introduced, which is defined as condition with no clinical
evidence of necrotic bone with various nonspecific clini-
cal signs21.
There is a discrepancy in BRONJ prevalence regard-
ing a number of medication parameters22–24:
• Underlying disease due to BPs use is more prevalent in
patients with malignant conditions (tumor related
hypercalcemia or bone metastasis) than in other pa-
tients with rheumatological and metabolic diseases;
• Osteonecrosis is more related to intravenous than oral
BPs treatment;
• Incidence of osteonecrosis is related to alkyl-BPs; in
case of non-nitrogenous BPs it is possible but very
rare.
Described incidences for BRONJ range from 3 to 17%
in multiple myeloma patients25–27, 1.2 to 11% in breast
cancer patients28–30, and 3 to 19% in prostate cancer
patients31. The risk of developing BRONJ in osteoporosis
patients treated with BPs is lower and is estimated at
one event per 20,000 to 100,000 patient-years32. The
most common aminoBPs associated with BRONJ are
pamidronate and zoledronate, followed by ibandronate
or alendronate23. Only a few cases of BRONJ in patients
taking alkyl-BPs have been published. There were rela-
tively few patients taking alkyl-BPs described, 28 alto-
gether, and out of that group 17 were also using nitrogen
BPs, which are also related to osteonecrosis33.
Apart from the dose, time and way of BPs use, a key
pharmacological feature is their binding affinity for bo-
ne, which depends on molecular stereochemistry. Rise-
dronate has a weaker binding affinity to bone tissue,
which results in: higher desorption, lower re-attach-
ment, and finally more diffusion in the bone34,35. The
highest BRONJ prevalence is in patients who received
zoledronate intravenously (53%); those who received pa-
midronate followed by zoledronate (27%), and finally,
those who only received pamidronate (19%). The preva-
lence of risedronate is only 0.5% as well as the combina-
tion of alendronate followed by zoledronate (0.5%)23.
Tooth extraction which can be an osteonecrosis trig-
ger is the main dental procedure associated with BRONJ
(67% of cases). Prosthetic appliances have an equally im-
portant role in BRONJ. Apart from the mylohyloid ridge,
critical sites for excessive pressure of the denture base
are palatine tori, and less frequently, mandibular tori
(7% of cases). A case of osteonecrosis associated with BPs
in patients with removable dentures was described36.
Even a case of direct nicotine effect (nicotine replace-
ment chewing gum) on the development of osteonecrosis
of the jaw without the effect of BPs was described37.
Filleul et al.23 found a spontaneous BRONJ development
in 26% of cases, without any particular trigger.
In contrast, Abu-Id et al.38 discovered that in 37.8% of
gathered cases BRONJ can be associated with prior tooth
extraction and in 28.6% of gathered cases with acute
periodontitis. Other risk factors are the following oral
surgical procedures: periodontal surgery (11.2%), dental
implants (3.4%) and apicotomy (0.8% of cases). Other
cases were identified as spontaneous BRONJ develop-
ment without any relation to any oral or dental factors.
Pathophysiological model for BRONJ
Some features of medications belonging to nitrogen
BPs, their application (peroral, intravenous), doses, the
relatively long-lasting half-life as well as simultaneous
intake of some other drugs such as corticosteroids and
comorbidity with other diseases (diabetes) contribute to
the vague clinical picture of a specific etiopathogenic
BRONJ model17,18,22.
Remodeling suppression
Antiosteoclastic pharmacological activity of BPs is the
cornerstone of the hypothesis of the development of
osteonecrosis of the jaw. It has been determined on the
animal model that high doses of risedronates and alen-
dronates administered orally (16 times higher than those
in clinical practice) reduced remodeling of the jaw in one
year from 40% to 5% whereas in the same period, remod-
eling of rib bones was reduced from 15% to 5%39. It is a
known fact that the alveolar bone shows ten times faster
bone turnover and the osteoclasts have a greater resor-
ptive activity40. Physiological balance between osteoclast
and osteoblast interaction can be compromised by bis-
phosphonate treatment. Oral infection or dental inter-
vention may increase remodeling rate in the jaw cortex41.
Hansen et al.42 obtained controversial results: while com-
paring patients with osteoradionecrosis and those with
BRONJ, and control subjects, a significantly larger num-
ber of osteoclasts in both groups of patients with osteo-
necrosis was determined.
Vascular compromise
BPs have an antiangiogenic effect on malignant tis-
sues and this is a part of their therapeutic effect43. How-
ever, the alveolar bone is highly vascularised bone tissue
and osteonecrotic lesions of the alveolar bone histolo-
gically still reveal the presence of hematologic elements.
Also, a clinically osteonecrotic lesion does not show avas-
cularity, but bleeds profusely during surgical procedu-
res40,44.
BPs toxicity
BPs cytotoxicity is possible on two levels: toxicity to
bone tissue and toxicity to soft oral tissue. With regard to
the vital enzyme effect of BPs in mevalonate cycle; dur-
ing the use of BPs, non-prenylated proteins are accumu-










lated in the cells. It is less possible to expect the lack of
prenylated proteins to be the basis of cytotoxicity to bone
since the synthesis of new proteins depends on concen-
tration of those which are non-prenylated45. Toxicity
could depend on the dose and duration due to long last-
ing (up to 12 years) BPs retention in bone tissue. How-
ever, there is no systemic toxicity of BPs to bone tissues;
it is localized to the jaw. Burr and Allen46 have showed on
animal model that treatment during 1–3 years with oral
BPs or 6 months with intravenous was associated with
development of necrotic areas with dead osteocytes in
the mandible and the rib. However, is it unclear whether
the toxic effect of BPs at high dose, natural process of cell
death or suppressed remodelling was responsible for de-
velopment of areas of necrotic tissue. It has been hypoth-
esised that BPs accumulated in bones directly cause epi-
thelial toxicity. This is explained by slow healing of
osteonecrotic lesions. During in vitro tests, BPs showed
strong inhibition of osteogenic as well as non-bone cells’,
such as fibroblasts, vitality47. BP toxicity to soft tissue
may be the reason why the skeletal system is directly ex-
posed to the oral environment through teeth and pe-
riodontal ligaments. Bone resorption and apposition are
biological processes occurring during physiological func-
tion of the stomatognathic system and during each orth-
odontic treatment. Using properly adjusted orthodontic
force does not cause excessive bone and/or tooth root re-
sorption.48 The results of the in vitro study by Coxon et
al.49 showed that if bone surfaces were not present, BPs
moved and acted on non-bone cells. In contrast, in pres-
ence of bone tissue, BPs were tightly bound to hydroxy-
apatite and induced apoptosis of osteoclasts.
Infection
Polymicrobial infection and periodontal disease may
contribute to development of BRONJ as a biofilm-associ-
ated infection. Periodontopathic bacteria, especially when
organized as microbial biofilms, could extend to the bone
through fistulas in the absence of mucosal break-
down50,51. Lipopolysaccharide production from gram-ne-
gative microbes stimulates bone resorption, for example,
Porphyromonas gingivalis species stimulates the forma-
tion of osteoclasts in periodontal tissues52. However, the
Actinomyces species is dominant: in the recent review by
Filleul et al.23 Actinomyces was present in 70% of all
cases in which microbiological data were presented.
Thumbigere-Math et al.53 found Actinomyces-like micro-
organisms in all bone specimens of 12 patients during
microbiological examination. Histological and microbio-
logical findings revealed that chronic Actinomyces infec-
tion was identical to chronic osteomyelitis. In all 11 ra-
diologically examined patients with BRONJ, [urlan
Popovi~ and Ko~ar54 found Actinomyces infection.
Discussion
Alveolar bone traumatisation factor can be important
for explanation of spontaneous osteonecrosis develop-
ment on the mylohyoid ridge after endotracheal intuba-
tion55. The mylohyoid ridge is a site of thin oral mucosis
which is often placed on the sharp edge in the posterior
sublingual region which serves as a point of attachment
to the mylohyoid muscle.
Bones without osteoclastic activity lack resorption
thus increasing bone mass but the long-term quality is
compromised due to continuous accumulation of micro-
fractures56. Osteonecrosis of the external auditory canal
which appeared in the form of non-healing ulceration in
only one patient with multiple myeloma undergoing BPs
treatment can be explained by embryonic development57.
Since osteonecrosis only appears on the bones of the jaw
(in 65% of cases on the mandible, 8% on both jaws), it can
be assumed that embryonic origin and biological features
of jaw bones in which remodelling occurs 10 times faster
than in other bones, have a part in the etiopathogenic ef-
fect. Also, the thin mucoperiosteal flap covering the alve-
olar bones is important for injury protection unlike the
thick layer of soft tissue covering the long bones23,40.
Additional etiopathogenic factors such as corticoste-
roid therapy or diabetes in BRONJ are questionable.
Since the majority of patients undergoing BPs therapy
are also treated for their main malignant condition, as
much as 55% of them underwent chemotherapy. Corti-
costeroid treatment was also common (32%), followed by
periodontal diseases (16%). However, direct correlation
has not been proved and there could also be comorbidi-
ties23. General immunosuppressive effects (corticoste-
roids) as well as local adverse effects of periodontal dis-
eases on healing of oral mucosa as well as of deeper
layers of the alveolar bone can also have a role in BRONJ
development. BRONJ were identified in only four pa-
tients with rheumatoid arthritis. The patients were us-
ing corticosteroids in treatment of the main diseases as
well as alendronate58.
Sarin et al.59 termed the comorbidity effects of several
immunosuppressive and/or bone remodelling suppres-
sive factors, including poor oral hygiene and bad habits,
»band-wagon« effect. This is supported by the fact that
Kos et al.60 did not find any differences between BRONJ
patients and controls, the latter being exposed to a num-
ber of different potential causes of osteonecrosis such as
tumours, chemotherapy, corticosteroids and stem cell
transplants. However, the role of Actinomyces colonies in
bone lesions is pointed out whereas BPs do not have a
dominant predisposing role in the development of osteo-
myelitis of the jaw.
An exact model of BRONJ etiopathogenesis does not
exist (Figure 1), yet some points of view have been defi-
nitely changed. Previously considered to be avascular ne-
crosis, BRONJ is, due to its pronounced infectious com-
ponent, more often related to osteomyelitis associated
with BPs61. BPs are important because of their cytoto-
xicity to bone tissue and possibly also to epithelial tissue
of the alveolar bone. Local trauma plays an important
role, in the form of a local surgical procedure such as
tooth extraction but as many as 26% of cases occur spon-
taneously according to Filleul et al.23. For this reason, ra-
diological diagnostics which enables an early detection of










BRONJ is very important. In spite of this, higher bone
matrix density does not often provide sufficiently differ-
ential radiological diversity with respect to the healthy
structure of the bone62. Panoramic dental radiography is
a radiological method in everyday dental practice, how-
ever, especially at stage 0, multi slice CT, cone bean CT,
and MRI diagostics can more specifically determine bone
abnormalities53,61.
In conclusion, the main principle in BRONJ treat-
ment is minimally invasive surgery. It is important to
take a microbiological swab due to high incidence of
Actinomyces-like microorganisms. It is questionable
whether BPs treatment should be interrupted if BRONJ
is diagnosed – a multidisciplinary approach should be
taken for each patient in order to determine the benefits
and possible consequences of drug therapy cessation
since BPs remain in the body for years after the begin-
ning of use.
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PATOFIZIOLOGIJA OSTEONEKROZE ^ELJUSTI U BOLESNIKA LIJE^ENIH BISFOSFONATIMA
S A @ E T A K
Bez obzira na dobro poznat mehanizam djelovanja bisfosfonata na stanice, raspravljen je embrionalni razvoj i spe-
cifi~na zbivanja u homeostazi alveolarne kosti. Etiopatogenetski mehanizam osteonekroze ~eljusti kosti povezanih s
lije~enjem bisfosfonatima nije jedinstveno obja{njen. Stavljen je naglasak na toksikolo{ki u~inak bisfosfonata na fizio-
logiju alveolarne kosti i trajni u~inak ekstrakcije zuba koju prati infekcija ekstrakcijske rane i njezina daljnja progresija
u dublje slojeve ko{tanog tkiva. Infekcija epitela uklju~uje mikrobiolo{ki nalaz roda Actinomyces. Izra`en je rizik u
onkolo{kih pacijenata pod intravenskom terapijom bisfosfonatima u relativno visokim dozama i tijekom duljeg vremen-
skog perioda, posebice visokopotentnim nitrogenim bisfosfonatima pamidronatom i zoledronatom. Ovaj pregled osteo-
nekroze ~eljusti povezane s bisfosfonatima stavlja ulogu bisfosfonata ~ak u drugi plan, a isti~e se zna~aj drugih predis-
poniraju}ih ~imbenika (kortikosteroidi, kemoterapije, tumori itd) za nastanka nekroze – to~nije osteomijelitisa ~eljusti
ako se uzme u obzir mikrobiolo{ka komponenta bolesti. Ne postoji zlatni standard u lije~enju osteonekroze ~eljusti,
~e{}e palijativna i minimalno invazivna, a ne oralno-kirur{ka terapija. Sve dok postoji znatan rizik za osteonekrozu
~eljusti u onkolo{kih bolesnika, oralno zdravlje je va`an ~imbenik u indikaciji intravenskog lije~enja bisfosfonatima.
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